These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16910543)

  • 21. Risperidone-related weight gain: genetic and nongenetic predictors.
    Lane HY; Liu YC; Huang CL; Chang YC; Wu PL; Lu CT; Chang WH
    J Clin Psychopharmacol; 2006 Apr; 26(2):128-34. PubMed ID: 16633140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Olanzapine plus venlafaxine in treatment-resistant depression.
    Devarajan S; Dursun SM
    J Psychopharmacol; 2005 Jul; 19(4):434-5. PubMed ID: 15983004
    [No Abstract]   [Full Text] [Related]  

  • 23. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK; Zalar B; Breskvar K; Dolzan V
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Personalized antipsychotic treatment: the adverse effects perspectives.
    Plesnicar BK
    Psychiatr Danub; 2010 Jun; 22(2):329-34. PubMed ID: 20562775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 5-HT1A C-1019G (rs6295) Predicts Aripiprazole Treatment Response Specifically for Cognitive and Depressive Symptoms in Schizophrenia.
    Chen SF; Shen YC
    J Clin Psychopharmacol; 2017 Feb; 37(1):114-118. PubMed ID: 28027114
    [No Abstract]   [Full Text] [Related]  

  • 26. [Status of and perspectives on psychiatric genomic medicine].
    Mors NP; Børglum AD
    Ugeskr Laeger; 2005 May; 167(20):2191-3. PubMed ID: 15987082
    [No Abstract]   [Full Text] [Related]  

  • 27. Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia.
    Mössner R; Schuhmacher A; Kühn KU; Cvetanovska G; Rujescu D; Zill P; Quednow BB; Rietschel M; Wölwer W; Gaebel W; Wagner M; Maier W
    Pharmacogenet Genomics; 2009 Jan; 19(1):91-4. PubMed ID: 18849890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of a 5-hydroxytryptamine 1A receptor gene polymorphism on the clinical response to fluvoxamine in depressed patients.
    Suzuki Y; Sawamura K; Someya T
    Pharmacogenomics J; 2004; 4(4):283-6. PubMed ID: 15148501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is pharmacogenetic CYP2D6 testing useful?
    Vetti HH; Molven A; Eliassen AK; Steen VM
    Tidsskr Nor Laegeforen; 2010 Nov; 130(22):2224-8. PubMed ID: 21109842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient.
    Conus P; Bondolfi G; Eap CB; Macciardi F; Baumann P
    Pharmacopsychiatry; 1996 May; 29(3):108-10. PubMed ID: 8738315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacogenetics and schizophrenia.
    Foster A; Miller DD; Buckley PF
    Psychiatr Clin North Am; 2007 Sep; 30(3):417-35. PubMed ID: 17720030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene expression changes in peripheral mononuclear cells from schizophrenic patients treated with a combination of antipsychotic with fluvoxamine.
    Chertkow Y; Weinreb O; Youdim MB; Silver H
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1356-62. PubMed ID: 17662512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia.
    Nagai G; Mihara K; Nakamura A; Suzuki T; Nemoto K; Kagawa S; Ohta I; Arakaki H; Kondo T
    Psychiatry Clin Neurosci; 2012 Oct; 66(6):518-24. PubMed ID: 23066770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypersalivation induced by olanzapine with fluvoxamine.
    Hori T; Makabe K; Nemoto K; Asada T
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):758-60. PubMed ID: 16574294
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose olanzapine for treatment-resistant schizophrenia.
    Roth BL
    J Clin Psychiatry; 2008 Feb; 69(2):176-7. PubMed ID: 18363451
    [No Abstract]   [Full Text] [Related]  

  • 36. CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits.
    Dorado P; Peñas-Lledó EM; Llerena A
    Pharmacogenomics; 2007 Nov; 8(11):1597-608. PubMed ID: 18034624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia.
    Liu W; Downing AC; Munsie LM; Chen P; Reed MR; Ruble CL; Landschulz KT; Kinon BJ; Nisenbaum LK
    Pharmacogenomics J; 2012 Jun; 12(3):246-54. PubMed ID: 21173788
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.
    Arranz MJ; de Leon J
    Mol Psychiatry; 2007 Aug; 12(8):707-47. PubMed ID: 17549063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The --1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients.
    Wang L; Fang C; Zhang A; Du J; Yu L; Ma J; Feng G; Xing Q; He L
    J Psychopharmacol; 2008 Nov; 22(8):904-9. PubMed ID: 18308786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP).
    Nozawa M; Ohnuma T; Matsubara Y; Sakai Y; Hatano T; Hanzawa R; Shibata N; Arai H
    Ther Drug Monit; 2008 Feb; 30(1):35-40. PubMed ID: 18223460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.